Table 1.
Comparison of recommended interventions for TEG abnormalities across the medical literature.
| Parameter | Treatment Values | Treatment Protocol |
|---|---|---|
| R (TEG) | R > 15 min 17 | 2 units of fresh frozen plasma(FFP) |
| R > 10 min 18 | FFP titrated over repeat TEG assays | |
| R < 4 min 19 | Anticoagulation | |
| R: 11-14 min 19 | 2 units FFP | |
| R > 14 min 19 | 4 units FFP | |
| R > 10 min 20 | FFP 10 mL/kg IBW | |
| ACT (RapidTEG w/Tissue Factor) | Initial ACT > 111-139s 21 | 2 units FFP |
| Initial ACT > 140s 21 | 2 units FFP + 10-pack cryoprecipitate (Cryo) + 1 unit platelet apheresis |
|
| Subsequent ACT > 110s 21 | 2 units FFP | |
| α-angle (TEG) | α < 45° 17 | 6 units Cryo |
| α < 45° 18 | 5 units Cryo | |
| α < 45° 19 | 0.06 units/kg Cryo | |
| α < 45° 20 | 5 units Cryo | |
| α-angle (RapidTEG) | α < 63° 21 | 10-pack Cryo |
| MA (TEG) | MA < 40 mm 17 | 10 units Platelets |
| MA < 55 mm 18 | 1 unit platelet apheresis | |
| MA > 73 mm 19 | Antiplatelet therapy | |
| MA: 46-54 mm 19 | 0.3 µg/kg DDAVP | |
| MA: 41-45 mm 19 | 1 unit platelet apheresis | |
| MA ≤ 40 mm 19 | 2 units of platelet apheresis | |
| MA < 55 mm 20 | 1 unit platelet apheresis | |
| MA (RapidTEG) | MA < 55 mm 21 | 1 unit platelet apheresis |
| Ly30 (RapidTEG) | Ly30 ≥ 7.5% (later reduced to ≥3%) 21 | Tranexamic acid 1 g IV |